The impact of IV Indomethacin Use on the total Serum Bilirubin Levels of very low birth weight Neonates
- At: 2016 FIP Congress in Buenos Aires (Argentina)
- Type: Poster
- By: HUANG, Chin-Shing (Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan, Department of Pharmacy, Kaohsiung, China Taiwan)
- Co-author(s): Chin-Shing Huang:|Chih-Chiang Tai:|Ching-Ling Tai:|Zon-Min Lee:
Ceftriaxone and sulfisoxazole are known to be contraindicated for use in neonates with hyperbilirubinemia due to their high protein-binding ability and daily doses. However, indomethacin, with very high protein-binding ability (99%), is commonly used for the treatment of patent ductus arteriosus in very low birth weight (VLBW) neonates.
To.. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.